SCHEMBL13313513

SCHEMBL13313513

NCc1cnc2c(O)cccn2c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ GAA P10253 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ MPI P34949 1/20 0.39
▸ HSD17B10 Q99714 2/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ CASP7 P55210 1/20 0.35
▸ MAPT P10636 4/20 0.34
▸ TP53 P04637 3/20 0.34
▸ POLB P06746 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PRMT5 O14744 1/20 0.32
▸ WDR77 Q9BQA1 1/20 0.32
▸ EGLN1 Q9GZT9 2/20 0.32
▸ VEGFA P15692 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10027225 0.86 LMNA (0.43) KDM4EALDH1A1GAALMNAGLA
SCHEMBL10027188 0.82 LMNA (0.40) KDM4EALDH1A1GAALMNAGLA
SCHEMBL13271288 0.82 MAPT (0.47) KDM4EALDH1A1GAALMNAHSD17B10
SCHEMBL23696295 0.81 LMNA (0.40) KDM4EALDH1A1GAALMNAGLA
SCHEMBL17802289 0.81 KDM4E (0.40) KDM4EALDH1A1GAALMNAGLA
SCHEMBL17808766 0.81 TP53 (0.45) KDM4EALDH1A1GAALMNAGLA
SCHEMBL17808887 0.81 CHEK1 (0.40) KDM4EALDH1A1GAALMNAGLA
Hydrochloric Acid SCHEMBL17802251 0.80 KDM4E (0.42) KDM4EALDH1A1GAALMNAGLA
SCHEMBL10027234 0.80 MAPT (0.43) KDM4EALDH1A1GAALMNAGLA
SCHEMBL13313514 0.80 KDM4E (0.42) KDM4EALDH1A1GAALMNAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 — — US disclosed
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 — — US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 — — US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS ACHE, PSEN1, PSEN2 KDM4E 3329/4885ALDH1A1 703/4885GAA 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback